{
    "ticker": "PSTX",
    "name": "PaxMedica, Inc.",
    "description": "PaxMedica, Inc. is a biotechnology company focused on developing innovative therapies for neurodevelopmental disorders and other complex conditions. Founded in 2017, PaxMedica aims to address the unmet medical needs of patients suffering from conditions such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). The company's flagship product, PAX-101, is a proprietary formulation of suramin, an FDA-approved drug traditionally used to treat African sleeping sickness. PaxMedica is advancing the clinical development of PAX-101 for ASD, leveraging suramin's unique mechanism of action that may help address the underlying biological factors associated with these disorders. The company is committed to conducting rigorous clinical trials to establish the safety and efficacy of its therapies, with a focus on improving the quality of life for patients and their families. With a team of experienced scientists and healthcare professionals, PaxMedica is dedicated to transforming the treatment landscape for neurodevelopmental disorders through innovative research and development efforts. The company's mission is to provide hope to patients and their families by unlocking new therapeutic options.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2017",
    "website": "https://www.paxmedica.com",
    "ceo": "Dr. T. N. M. K. H. Chinthaka",
    "social_media": {
        "twitter": "https://twitter.com/PaxMedica",
        "linkedin": "https://www.linkedin.com/company/paxmedica"
    },
    "investor_relations": "https://www.paxmedica.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. T. N. M. K. H. Chinthaka",
            "position": "CEO"
        },
        {
            "name": "Dr. Joseph A. F. P. S. L. P. P. C. Chukwuma",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PAX-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "PaxMedica, Inc. | Innovative Therapies for Neurodevelopmental Disorders",
        "meta_description": "Discover PaxMedica, Inc., a biotechnology company focused on developing therapies for neurodevelopmental disorders like autism. Learn about their clinical advancements and mission.",
        "keywords": [
            "PaxMedica",
            "Neurodevelopmental Disorders",
            "ASD",
            "ADHD",
            "Biotechnology",
            "Suramin"
        ]
    },
    "faq": [
        {
            "question": "What is PaxMedica known for?",
            "answer": "PaxMedica is known for developing innovative therapies for neurodevelopmental disorders, particularly its lead product, PAX-101."
        },
        {
            "question": "Who is the CEO of PaxMedica?",
            "answer": "Dr. T. N. M. K. H. Chinthaka is the CEO of PaxMedica, Inc."
        },
        {
            "question": "Where is PaxMedica headquartered?",
            "answer": "PaxMedica is headquartered in New York, New York, USA."
        },
        {
            "question": "What is PAX-101?",
            "answer": "PAX-101 is a proprietary formulation of suramin being developed for the treatment of autism spectrum disorder."
        },
        {
            "question": "When was PaxMedica founded?",
            "answer": "PaxMedica was founded in 2017."
        }
    ],
    "competitors": [
        "VRTX",
        "NVAX",
        "MNKD"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "REGN"
    ]
}